beta

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data from aninvestigational study released at the American Diabetes Association(ADA) 67th Annual Scientific Sessions showed that initialcombination therapy with Januvia(TM) (sitagliptin) and metformindemonstrated significant improvement in markers of beta cellfunction in patients with type 2 diabetes. Pancreatic islet betacell function determines...

Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin

VIENNA, Va., June 20, 2007 /PRNewswire/ -- Modigene Inc., aNevada corporation today announced the successful completion ofpharmacokinetic and pharmacodynamic pre-clinical experiments forlong-acting human growth hormone, long-acting interferon beta andlong-acting erythropoietin. Modigene's pharmacodynamic and pharmacokinetic pre-clinicalexperiments demonstrated superb durability of...

Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor AP 12009 to be Presented

REGENSBURG, Germany, May 10th, 2007 - AntisensePharma today announced, that the abstract entitled“Preliminary Results of a Phase I/II-Study in PancreaticCarcinoma, Malignant Melanoma, and Colorectal Carcinoma with theTGF-beta2 Inhibitor AP 12009” has been selected for posterpresentation at the 43rd Annual Meeting of the American Society ofClinical Oncology (ASCO)...

Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron

BOSTON, May 03, 2007 /PRNewswire/ -- Bayer HealthCarePharmaceuticals announced today the results of three clinicalstudies with Betaseron(R) (interferon beta-1b), presented this weekat the American Academy of Neurology's (AAN) 59th Annual Meeting,demonstrating early efficacy, long-term tolerability, and highpatient satisfaction with treatment in patients with relapsingforms of multiple sc...

Immediate Treatment of Early MS Patients with Betaferon Significantly Delayed Permanent Disability

Risk to confirmed EDSS progression reduced by 40 percent comparedto delayed treatment BERLIN, May 1, 2007 – Bayer Schering Pharma AG,Germany, announced today new data, which show that immediateinitiation of Betaferon® (interferon beta-1b) treatment inpatients with a first event suggestive of multiple sclerosis (MS)can significantly reduce the risk of permanent neurolog...

First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron Significantly Delayed Permanent Disability

Risk to confirmed EDSS progression reduced by 40 percent comparedto delayed treatment BOSTON, May 01, 2007 /PRNewswire/ -- Bayer HealthCarePharmaceuticals announced today new data, which show that immediateinitiation(1) of Betaseron(R) (interferon beta-1b) treatment inpatients with a first event suggestive of multiple sclerosis (MS)can significantly reduce the risk of permanent neurologic...

First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

KANSAS CITY, Mo.--(BUSINESS WIRE)--Apr 11, 2007 - A comparison ofthe long-term economic outcomes of four immunomodulatory drugtherapies combined with symptom management versus symptommanagement alone revealed that COPAXONE(R) (glatiramer acetateinjection) was the most cost-effective treatment strategy forrelapsing-remitting multiple sclerosis (RRMS). The study providesthe first pharmacoecon...

Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment

WAYNE, N.J., April 02, 2007 /PRNewswire/ -- Berlex, Inc., a U.S.affiliate of Bayer Schering Pharma AG, Germany, announced today theresults of a retrospective study demonstrating that the presence ofneutralizing antibodies (NAbs) that can develop in response toBetaseron(R) (interferon beta-1b) therapy did not predict clinicalresponse in patients with multiple sclerosis (MS).(1) The studyl...

Interferon Beta DNA Treatment Delivered with Ichor Technology Reduces Atherosclerosis Progression in Mice

Summary: Proprietary DNA delivery technology enables sustainedInterferon-beta production from muscle cells - reducesatherosclerosis progression in mouse model of heart disease NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Research conductedat Cleveland Clinic and presented today at the American College ofCardiology's 58th Annual Scientific Session showed that a singleadministration of DNA...